Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
synthetic cannabinoid
|
| gptkbp:actsOn |
cannabinoid receptor agonist
|
| gptkbp:binding_affinity_CB1 |
Ki = 2.87 nM
|
| gptkbp:binding_affinity_CB2 |
Ki = 0.88 nM
|
| gptkbp:CASNumber |
1400742-17-7
|
| gptkbp:category |
recreational drug
synthetic cannabinoid indazole-3-carboxamide |
| gptkbp:chemicalFormula |
C18H26N4O2
|
| gptkbp:first_identified_year |
2012
|
| gptkbp:firstReported |
gptkb:Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
AB-PINACA
|
| gptkbp:IUPACName |
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide
|
| gptkbp:legal_status_in_UK |
Class B drug
|
| gptkbp:legalStatus |
Schedule I controlled substance
|
| gptkbp:molecularWeight |
326.43 g/mol
|
| gptkbp:relatedTo |
gptkb:5F-AB-PINACA
AB-FUBINACA |
| gptkbp:routeOfAdministration |
oral
inhalation |
| gptkbp:sideEffect |
death
anxiety paranoia seizures tachycardia hallucinations |
| gptkbp:usedFor |
recreational drug
|
| gptkbp:bfsParent |
gptkb:MAU-209
|
| gptkbp:bfsLayer |
7
|